199 related articles for article (PubMed ID: 38145461)
1. Molecular characteristics of early-onset pancreatic ductal adenocarcinoma.
Debernardi S; Liszka L; Ntala C; Steiger K; Esposito I; Carlotti E; Baker AM; McDonald S; Graham T; Dmitrovic B; Feakins RM; Crnogorac-Jurcevic T
Mol Oncol; 2024 Mar; 18(3):677-690. PubMed ID: 38145461
[TBL] [Abstract][Full Text] [Related]
2. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
3. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
[TBL] [Abstract][Full Text] [Related]
4. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
5. Clinical Effect of Driver Mutations of
Gu Y; Ji Y; Jiang H; Qiu G
Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
[No Abstract] [Full Text] [Related]
6. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
7. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
[TBL] [Abstract][Full Text] [Related]
8. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.
Masugi Y; Takamatsu M; Tanaka M; Hara K; Inoue Y; Hamada T; Suzuki T; Arita J; Hirose Y; Kawaguchi Y; Nakai Y; Oba A; Sasahira N; Shimane G; Takeda T; Tateishi K; Uemura S; Fujishiro M; Hasegawa K; Kitago M; Takahashi Y; Ushiku T; Takeuchi K; Sakamoto M;
J Pathol Clin Res; 2023 Sep; 9(5):339-353. PubMed ID: 37291757
[TBL] [Abstract][Full Text] [Related]
9. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma.
Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL
Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536
[TBL] [Abstract][Full Text] [Related]
10. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.
Schlitter AM; Segler A; Steiger K; Michalski CW; Jäger C; Konukiewitz B; Pfarr N; Endris V; Bettstetter M; Kong B; Regel I; Kleeff J; Klöppel G; Esposito I
Sci Rep; 2017 Feb; 7():41064. PubMed ID: 28145465
[TBL] [Abstract][Full Text] [Related]
11. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
Sun H; Zhang B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic ductal adenocarcinomas from Mexican patients present a distinct genomic mutational pattern.
Sanchez P; Espinosa M; Maldonado V; Barquera R; Belem-Gabiño N; Torres J; Cravioto A; Melendez-Zajgla J
Mol Biol Rep; 2020 Jul; 47(7):5175-5184. PubMed ID: 32583281
[TBL] [Abstract][Full Text] [Related]
13. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma.
Zhou Y; Jin J; Ji Y; Zhang J; Fu N; Chen M; Wang J; Qin K; Jiang Y; Cheng D; Deng X; Shen B
J Transl Med; 2023 Dec; 21(1):872. PubMed ID: 38037073
[TBL] [Abstract][Full Text] [Related]
14. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
[TBL] [Abstract][Full Text] [Related]
15. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract][Full Text] [Related]
17. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
[TBL] [Abstract][Full Text] [Related]
18. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
[TBL] [Abstract][Full Text] [Related]
19. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of multiple pancreatic cancers involves multicentric carcinogenesis and intrapancreatic metastasis.
Fujita Y; Matsuda S; Sasaki Y; Masugi Y; Kitago M; Yagi H; Abe Y; Shinoda M; Tokino T; Sakamoto M; Kitagawa Y
Cancer Sci; 2020 Feb; 111(2):739-748. PubMed ID: 31799787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
